In some trials, some patients with PD-L1-negative tumors have also shown clinical responses to PD-1 inhibitors, with tumor regression or disease stabilization, and in some research, BMI has been shown to be related to the efficacy of PD-1 inhibitors [10,11]. The gene discussed is PDCD1; the disease is neoplasm.